2023
Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy
Hertz D, Tofthagen C, Rossi E, Bernasconi D, Lim J, Carlson M, Sheffield K, Nekhlyudov L, Grech L, Von Ah D, Mayo S, Ruddy K, Chan A, Alberti P, Lustberg M, Tanay M. Patient perceptions of altering chemotherapy treatment due to peripheral neuropathy. Supportive Care In Cancer 2023, 32: 48. PMID: 38129602, DOI: 10.1007/s00520-023-08209-0.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyNeurotoxic chemotherapy treatmentChemotherapy treatmentSymptom resolutionPeripheral neuropathySevere chemotherapy-induced peripheral neuropathyCommon reason participantsMethodsA cross-sectional online surveyBetter patient educationCross-sectional online surveyNeurotoxic chemotherapyCIPN symptomsMedian ageMost patientsTreating clinicianLong-term benefitsPatients' perceptionsPatient educationPractice guidelinesTreatment goalsClinicians' understandingTreatment efficacyConclusionsThis surveyPatientsSymptomsAdolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bhatia S, Pappo A, Acquazzino M, Allen-Rhoades W, Barnett M, Borinstein S, Casey R, Choo S, Chugh R, Dinner S, Ermoian R, Fair D, Federman N, Folbrecht J, Gandhi S, Germann J, Goldsby R, Hayashi R, Huang A, Huang M, Jacobs L, Lee-Miller C, Link M, Livingston J, Lustberg M, Malogolowkin M, Oeffinger K, Pratilas C, Reed D, Skiles J, von Mehren M, Yeager N, Montgomery S, Hang L. Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 851-880. PMID: 37549914, DOI: 10.6004/jnccn.2023.0040.Peer-Reviewed Original ResearchConceptsYoung Adult OncologyAYA patientsAdult oncologyNCCN guidelinesNCCN Clinical Practice GuidelinesClinical practice guidelinesSupportive care servicesFertility counselingRisk factorsComprehensive carePractice guidelinesCare servicesPatientsOlder adultsOncologyCancerUnique needsGuidelinesAdolescentsBehavioral issuesDiagnosisCareMitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
Lustberg M, Kuderer N, Desai A, Bergerot C, Lyman G. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nature Reviews Clinical Oncology 2023, 20: 527-542. PMID: 37231127, PMCID: PMC10211308, DOI: 10.1038/s41571-023-00776-9.Peer-Reviewed Original ResearchConceptsAdverse eventsEvidence-based clinical practice guidelinesChemotherapy-associated adverse eventsNon-pharmacological treatment strategiesAdverse effectsClinical practice guidelinesAdverse treatment effectsCourse of therapyTotality of evidenceQuality of lifeTerms of survivalRisk assessment toolOptimal therapyCancer survivorsRisk factorsOncology practiceTreatment strategiesPractice guidelinesUnderlying biological mechanismsAppropriate managementAnticancer treatmentCancer treatmentEffective interventionsTreatment effectsChemotherapyFramework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)
Stoller S, Capozza S, Alberti P, Lustberg M, Kleckner I. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care In Cancer 2023, 31: 293. PMID: 37086308, DOI: 10.1007/s00520-023-07734-2.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neurotoxicityPhysical therapy guidelinesPhysical therapistsPhysical therapyCIPN assessmentPeripheral neurotoxicityOncology teamTherapy guidelinesHome-based exercise prescriptionBurden of chemotherapyManual therapy interventionsClinical practice guidelinesPhysical therapy assessmentLimited effective treatmentsQuality of lifePhysical performance measuresSymptom management researchCIPN treatmentNeurologic symptomsMotor dysfunctionPatient functionExercise prescriptionAerobic trainingChemotherapy agentsPractice guidelines
2014
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
Hershman D, Lacchetti C, Dworkin R, Lavoie Smith E, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg M, Paice J, Schneider B, Smith M, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal Of Clinical Oncology 2014, 32: 1941-1967. PMID: 24733808, DOI: 10.1200/jco.2013.54.0914.Peer-Reviewed Original ResearchMeSH KeywordsAdultAminesAmitriptylineAnalgesicsAnticonvulsantsAntidepressive Agents, TricyclicAntineoplastic AgentsBaclofenComorbidityCyclohexanecarboxylic AcidsDrug Therapy, CombinationDuloxetine HydrochlorideEvidence-Based MedicineGabapentinGamma-Aminobutyric AcidGelsHumansIncidenceKetamineNeoplasmsNeuralgiaPeripheral Nervous System DiseasesQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSurvivorsThiophenesTreatment OutcomeUnited StatesConceptsChemotherapy-induced peripheral neuropathyPeripheral neuropathyPrimary outcomePrevention of CIPNTreatment of CIPNClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineNeuropathic pain conditionsSeverity of neuropathyClinical practice guidelinesPatient-reported outcomesAdult cancer survivorsQuality of lifeSystematic literature searchEvidence-based guidanceDifferent time pointsPain conditionsCancer survivorsTreatment optionsTricyclic antidepressantsPractice guidelinesAdult cancersNeurophysiologic changesEligibility criteriaTreatment approaches